Ngenla Subcutaneous Injection Special Investigation

The purpose of this study is to learn about the long-term safety and effects of Ngenla. Ngenla is approved for treatment of GHD (Growth hormone deficiency) without epiphyseal closure under daily medical practice.We are seeking participants who:Have GHD without epiphyseal closure and receiving Ngenla for the first time.Are boys less than 15 years or girls less than 13 years of age at the start of treatment with Ngenla.All patients in this study will receive Ngenla according to the prescriptions. We will monitor their experiences for a long time. This will help us to determine the safety and effects of Ngelna for long-term use.Participants will take part in the study from the date of first Ngenla treatment until November 30, 2027.

Patients who satisfy all of the registration criteria are subject to this study.Registration criteriaPatients with GHD without epiphyseal closure who receive this drug for the first time after the date of contract for this study.Boys who are less than 15 years and girls who are less than 13 years of chronological age at the start of treatment with this drug.